[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629980":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":46,"collaborators":50,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":20,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":82,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Treatment Arm","EXPERIMENTAL","Participants with recurrent malignant glioma will receive IL13Rα2 CAR-T cells secreting anti-PD-L1 antibody within a single-arm, open-label study framework. Two administration strategies are planned according to investigator assessment and protocol procedures: peripheral intravenous infusion alone, or peripheral intravenous infusion combined with intraventricular injection. Dose escalation is planned, including 1×10\\^6 cells\u002Fkg, 3×10\\^6 cells\u002Fkg, and 1×10\\^7 cells\u002Fkg for peripheral infusion. For the combined administration strategy, the intraventricular dose is 20%-30% of the peripheral dose, adjusted according to tolerability.",[13],"Biological: IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody","Autologous IL13Rα2-targeted CAR-T cells engineered to secrete anti-PD-L1 antibody will be administered after lymphodepleting pretreatment. The study includes peripheral intravenous infusion alone or peripheral intravenous infusion combined with intraventricular injection. Peripheral dose-escalation levels are 1×10\\^6 cells\u002Fkg, 3×10\\^6 cells\u002Fkg, and 1×10\\^7 cells\u002Fkg. In the combined administration strategy, the intraventricular dose is 20%-30% of the peripheral dose, with adjustment based on patient tolerability. Patients will be monitored in the ICU or a dedicated inpatient setting during infusion and for adverse events including CRS and ICANS after infusion.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ming Yang, Medical Doctor","CONTACT","+86 138 1065 5237","yangming@cicams.ac.cn",[28],{"facility":29,"status":20,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"National Cancer Center\u002FNational Clinical Research Center for Cancer\u002FCancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","Beijing","Beijing Municipality","100021","China","CN",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Hongliang Mao, Medical Doctor","+86 18756909374","Mao.HL@hotmail.com",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Ming Yang","Clinical Professor",[51,54,56],{"name":52,"class":53},"Pecking Union Medical College Hospital, Department of Neurosurgery","UNKNOWN",{"name":55,"class":53},"Emergency General Hospital, Department of Neurosurgery",{"name":57,"class":6},"Peking University International Hospital","100629980","phase-1-il13r2-car-t-cells-secreting-anti-pd-l1-antibody-for-recurrent-malignant-glioma-100629980",false,"NCT07481721","IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma","A Multicenter, Open-Label, Non-Randomized, Single-Arm Investigator-Initiated Trial to Evaluate the Safety and Efficacy of IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody in Patients With Recurrent Malignant Glioma","APIC-RG","Inclusion Criteria:\n\n* Recurrent malignant glioma (WHO grade IV)\n* Pathologically confirmed and imaging-defined recurrent glioma\n* ECOG score of 0-2\n* Age \\>=18 years\n* Male or female\n* Life expectancy \\>3 months\n\nExclusion Criteria:\n\n* Severe immune suppression or autoimmune diseases\n* Severe cardiac, liver, kidney, or other major organ dysfunction\n* Pregnant or breastfeeding women\n* Prior treatment with immune checkpoint inhibitors or other immunotherapies\n* Other conditions posing significant risk to the patient or preventing adherence to the study protocol","ALL","18 Years",{"count":69,"type":70},24,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","This clinical study is designed to evaluate the safety and efficacy of IL13Rα2 CAR-T cells secreting anti-PD-L1 antibody in patients with recurrent malignant glioma. This trial is a multicenter, open-label, non-randomized, single-arm investigator-initiated trial (IIT). Patients who have recurrent malignant glioma will receive IL13Rα2 CAR-T cell therapy and will be monitored for safety, adverse events (AEs), and efficacy outcomes, including overall survival (OS) and progression-free survival (PFS). The study will help assess the potential of this innovative therapy in the treatment of glioma and its ability to control tumor growth by targeting both IL13Rα2 and PD-L1.",[76],"Recurrent Malignant Glioma",[78,79,76,80,81],"IL13Rα2 CAR-T","PD-L1-secreting CAR-T","Cell Therapy","Immunotherapy","NOT_YET_RECRUITING","2026-03-13",{"date":85,"type":86},"2026-03-19","ACTUAL",{"date":88,"type":70},"2026-05-01",{"date":90,"type":70},"2027-12-31",{"name":48,"class":6},1]